
Myelodysplastic syndrome Program in Pharmaceutical Benefits Scheme (PBS) 012-18051125

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised lenalidomide for
patients with myelodysplastic syndrome (MDS).

Myelodysplastic syndrome and listing dates

Myelodysplastic syndromes (MDS) are a group of disorders caused by
poorly formed or dysfunctional blood cells.

Listing dates are:

-   lenalidomide - 1 October 2013

For more information, see Written Authority Required for Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Manage work items in PaNDA

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
